PKP triple procedure with a 25G is a safe treatment option

Article

Penetrating keratoplasty (PKP) triple procedures with a 25G system is a safe and effective treatment option.

Penetrating keratoplasty (PKP) triple procedures with a 25G system is a safe and effective treatment option, claims a study in the journal Cornea.

Dr Shiro Higaki et al., Department of Ophthalmology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan, divided 30 patients into three groups. The groups were 12 eyes of 12 patients in the PKP group that underwent 25G vitrectomy, 9 eyes and 9 patients that underwent 20G vitrectomy and 9 eyes of 9 patients in the non-core vitrectomy group who underwent PKP without core vitrectomy.

The success rates of the IOL implantation were 97.1%, 88.9% and 66.7% for the 25G, 20G, and non-core vitrectomy groups, respectively. At 69 minutes for an average operation time the 25G group demonstrated the shortest time, compared to 82 minutes, and 90 minutes in the 20G group and the non-core vitrectomy group, respectively.

The PKP triple procedure with the 25G system offers a higher success rate of IOL implantation and significantly reduced operation time compared to 20G and non-core vitrectomy.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Related Content
An image of two containers of vitamin B supplements. Concept image for choline, b6, b9 and b12 vitamins in neuroprotection for glaucoma. ©itsflowingtothesoul – stock.adobe.com

Research indicates B vitamins and choline provide neuroprotection against glaucoma

Lynda Charters
May 26th 2025
Article

Vitamins B6, B9 and B12 were found to be neuroprotective against retinal ganglion cell death

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
A single-shot, 130-degree OCTA image of the retina captured using DREAM OCT. Image courtesy of Intalight

EMA issues CE mark for DREAM OCT (Intalight)

Jordana Joy
May 22nd 2025
Article

The OCT platform offers deep imaging depth, rapid sweeping speed, extensive scan range, accurate results and multimodal imaging capabilities

A woman with glasses helps a child, who may be her daughter, use a tablet. Concept image for online school, homeschool, screen time, myopia, and paediatric astigmatism. Image credit: ©K2L Family – stock.adobe.com

Research links COVID-19 to prevalence and severity of paediatric astigmatism

Lynda Charters
May 20th 2025
Article

The study found an increase in both refractive astigmatism and corneal astigmatism among a patient population of schoolchildren

A pharmacist helps a customer access medication. Concept image for neovascular age-related macular degeneration eye drop treatment therapy. Image credit: ©Gorodenkoff – stock.adobe.com

Topline results from investigational nAMD drop SYL1801 (Sylentis)

Kassi Filkins
May 19th 2025
Article

Three dose level cohorts of the small interfering RNA therapeutic were evaluated in a double-blind study

A group of elderly women navigate a street in Europe. Concept image for age-related macular degeneration and geographic atrophy. Image credit: ©Zelma – stock.adobe.com

How patients navigate quality-of-life challenges associated with geographic atrophy

Lynda Charters
May 15th 2025
Article

Investigators sought to understand the diagnostic path, symptoms, quality of life impact and coping mechanisms of patients with GA in western Europe and the United States

© 2025 MJH Life Sciences

All rights reserved.